The European Medicines Agency’s Committee for Medicinal Products for Human Use has endorsed nine medicines for approval at its May meeting, including Novartis’ Aimovig, the first human monoclonal antibody for migraine prevention. More: Novartis’ Aimovig leads CHMP recommendations Source: News
read moreMerck’s Keytruda already boasts a standalone approval for lung cancer patients who haven’t been treated before, so long as their tumors bear high levels of the PD-L1 biomarker. But it could soon reach beyond that group, thanks to new data
read moreAt this year’s ASCO meeting, squamous lung cancer has elbowed non-squamous disease off center stage—but once again, it’s Merck & Co. stealing the spotlight. Sunday, the drugmaker’s PD-1 med Keytruda showed it could cut the risk of disease worsening or
read moreAmgen, in a two-sentence announcement today, said it received a complete response letter for the biosimilar of Roche’s cancer med Herceptin it developed with Allergan. It marks the third Herceptin biosimilar that has been stalled by the FDA but has
read moreThe 2-mg dose of Eli Lilly and Incyte’s rheumatoid arthritis drug Olumiant picked up an FDA approval after independent experts flagged safety concerns on the 4-mg dose. And with a black-box warning on its label, the new med will face
read moreAfter learning Aimovig’s official price—$6,900 per year—ICER revised its work to conclude the migraine prevention drug is cost-effective when other options fail. More: Thanks to lower-than-expected price, ICER backs Amgen's Aimovig—but only after other drugs fail Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals